These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 31125485)

  • 1. Drug-induced alloreactivity: A new paradigm for allorecognition.
    D'Orsogna LJ; Almeida CM; van Miert P; Zoet YM; Anholts JDH; Chopra A; Watson M; Witt C; John M; Claas FHJ
    Am J Transplant; 2019 Sep; 19(9):2606-2613. PubMed ID: 31125485
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards depersonalized abacavir therapy: chemical modification eliminates HLA-B*57 : 01-restricted CD8+ T-cell activation.
    Naisbitt DJ; Yang EL; Alhaidari M; Berry NG; Lawrenson AS; Farrell J; Martin P; Strebel K; Owen A; Pye M; French NS; Clarke SE; O'Neill PM; Park BK
    AIDS; 2015 Nov; 29(18):2385-95. PubMed ID: 26372480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of abacavir-specific effector and proliferating functions of CD8 T cells in abacavir-treated HIV-1 patients.
    Faridi RM; Patel S; Dharmani-Khan P; Gill J; Berka N; Khan FM
    Microbiol Immunol; 2020 Mar; 64(3):210-218. PubMed ID: 31876322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity.
    Norcross MA; Luo S; Lu L; Boyne MT; Gomarteli M; Rennels AD; Woodcock J; Margulies DH; McMurtrey C; Vernon S; Hildebrand WH; Buchli R
    AIDS; 2012 Jul; 26(11):F21-9. PubMed ID: 22617051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of HIV-specific T cell clonotypes using allogeneic HLA.
    Almeida CA; van Miert P; O'Driscoll K; Zoet YM; Chopra A; Watson M; de Santis D; Witt C; John M; Claas FHJ; D'Orsogna LJ
    Cell Immunol; 2017 Jun; 316():32-40. PubMed ID: 28372798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abacavir-reactive memory T cells are present in drug naïve individuals.
    Lucas A; Lucas M; Strhyn A; Keane NM; McKinnon E; Pavlos R; Moran EM; Meyer-Pannwitt V; Gaudieri S; D'Orsogna L; Kalams S; Ostrov DA; Buus S; Peters B; Mallal S; Phillips E
    PLoS One; 2015; 10(2):e0117160. PubMed ID: 25674793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A sensitive and rapid alternative to HLA typing as a genetic screening test for abacavir hypersensitivity syndrome.
    Martin AM; Krueger R; Almeida CA; Nolan D; Phillips E; Mallal S
    Pharmacogenet Genomics; 2006 May; 16(5):353-7. PubMed ID: 16609367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinetics of Abacavir-Induced Remodelling of the Major Histocompatibility Complex Class I Peptide Repertoire.
    Illing PT; van Hateren A; Darley R; Croft NP; Mifsud NA; King S; Kostenko L; Bharadwaj M; McCluskey J; Elliott T; Purcell AW
    Front Immunol; 2021; 12():672737. PubMed ID: 34093574
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine profiling in abacavir hypersensitivity patients.
    Almeida CA; Martin AM; Nolan D; Lucas A; Cameron PU; James I; Phillips E; Mallal S
    Antivir Ther; 2008; 13(2):281-8. PubMed ID: 18505179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA-B*57:01(+) abacavir-naive individuals have specific T cells but no patch test reactivity.
    Schnyder B; Adam J; Rauch A; Thurnheer MC; Pichler WJ
    J Allergy Clin Immunol; 2013 Sep; 132(3):756-758. PubMed ID: 23706613
    [No Abstract]   [Full Text] [Related]  

  • 11. HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects.
    Small CB; Margolis DA; Shaefer MS; Ross LL
    BMC Infect Dis; 2017 Apr; 17(1):256. PubMed ID: 28399804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.
    Mallal S; Nolan D; Witt C; Masel G; Martin AM; Moore C; Sayer D; Castley A; Mamotte C; Maxwell D; James I; Christiansen FT
    Lancet; 2002 Mar; 359(9308):727-32. PubMed ID: 11888582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive screening for human immunodeficiency virus type 1 subtype-specific CD8 cytotoxic T lymphocytes and definition of degenerate epitopes restricted by HLA-A0207 and -C(W)0304 alleles.
    Currier JR; deSouza M; Chanbancherd P; Bernstein W; Birx DL; Cox JH
    J Virol; 2002 May; 76(10):4971-86. PubMed ID: 11967314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cells from HLA-B*57:01+ human subjects are activated with abacavir through two independent pathways and induce cell death by multiple mechanisms.
    Bell CC; Faulkner L; Martinsson K; Farrell J; Alfirevic A; Tugwood J; Pirmohamed M; Naisbitt DJ; Park BK
    Chem Res Toxicol; 2013 May; 26(5):759-66. PubMed ID: 23541086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive evaluation of two HLA-B17 monoclonal antibodies for flow cytometry-based HLA-B57/B58 screening prior to abacavir prescription.
    Stevens R; Coates E; Street J; Cook E; Darke C
    Int J Immunogenet; 2013 Aug; 40(4):311-5. PubMed ID: 23280011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity.
    Chessman D; Kostenko L; Lethborg T; Purcell AW; Williamson NA; Chen Z; Kjer-Nielsen L; Mifsud NA; Tait BD; Holdsworth R; Almeida CA; Nolan D; Macdonald WA; Archbold JK; Kellerher AD; Marriott D; Mallal S; Bharadwaj M; Rossjohn J; McCluskey J
    Immunity; 2008 Jun; 28(6):822-32. PubMed ID: 18549801
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
    Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
    Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan.
    Sun HY; Hung CC; Lin PH; Chang SF; Yang CY; Chang SY; Chang SC
    J Antimicrob Chemother; 2007 Sep; 60(3):599-604. PubMed ID: 17631508
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [HLA-B*5701 and abacavir hypersensitivity reaction].
    Servonnet A; Leclercq E; Delacour H; Ceppa F
    Pathol Biol (Paris); 2010 Dec; 58(6):e95-100. PubMed ID: 19243901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High responsiveness of HLA-B57-restricted Gag-specific CD8+ T cells in vitro may contribute to the protective effect of HLA-B57 in HIV-infection.
    Jansen CA; Kostense S; Vandenberghe K; Nanlohy NM; De Cuyper IM; Piriou E; Manting EH; Miedema F; van Baarle D
    Eur J Immunol; 2005 Jan; 35(1):150-8. PubMed ID: 15593302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.